Schumann, K, Mauch, C, Klespe, KC, Loquai, C, Nikfarjam, U, Schlaak, M, Akcetin, L
, Kolblinger, P, Hoellwerth, M, Meissner, M, Mengi, G, Braun, AD, Mengoni, M, Dummer, R, Mangana, J, Sindrilaru, MA, Radmann, D, Hafner, C, Freund, J, Rappersberger, K, Weihsengruber, F, Meiss, F, Reinhardt, L, Meier, F, Rainer, B, Richtig, E, Ressler, JM, Holler, C, Eigentler, T, Amaral, T, Peitsch, WK, Hillen, U, Harth, W, Ziller, F, Schatton, K, Gambichler, T, Susok, L, Maul, LV, Laubli, H
, Debus, D, Weishaupt, C, Borger, S, Sievers, K, Haferkamp, S, Zenderowski, V, Nguyen, V, Wanner, M, Gutzmer, R, Terheyden, P, Kahler, K, Emmert, S, Thiem, A, Sachse, M, Gercken-Riedel, S, Kaune, KM, Thoms, KM, Heinzerling, L, Heppt, MV, Tratzmiller, S, Hoetzenecker, W, Ollinger, A, Steiner, A, Peinhaupt, T, Podda, M, Schmid, S, Wollina, U, Biedermann, T & Posch, C 2023, '
Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland',
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY , vol. 37, no. 5, pp. 894-906.
https://doi.org/10.1111/jdv.18779